Advancing the early detection of curable cancers

Applying Genetic Cytology to routinely collected patient samples

PapGene, Inc.

Founded by world leading cancer researchers from Johns Hopkins University,
we are commercializing advanced molecular tests for the early detection of cancers
by applying innovative massively parallel sequencing techniques
to routinely collected cytology samples.

Team

Founders
Bert Vogelstein, M.D.

Bert was the first scientist to elucidate the molecular basis of a common human cancer. He is the Clayton Professor of Oncology and Pathology and Co-Director of the Ludwig Institute at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins University School of Medicine.

Kenneth W. Kinzler, Ph.D.

Ken is a world recognized expert on the molecular and genetic analysis of human cancer who has been responsible for numerous advances in this field.  He is a Professor of Oncology and Co-Director of the Ludwig Institute at SKCCC at Johns Hopkins University School of Medicine.

Nickolas Papadopoulos, Ph.D.

Nick is internationally known as a co‐discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer. He is currently Director of Translational Genetics at the Ludwig Centre for Cancer Genetics and Therapeutics and Professor of Oncology at SKCCC.


 
Shibin Zhou, M.D., Ph.D.

Shibin is an expert in developing new cancer therapeutic approaches involving biologics, nanoparticles and manipulation of anticancer immune responses. He is an Assoc. Professor of Oncology at SKCCC and Director of Experimental Therapeutics at the Ludwig Center for Cancer Genetics and Therapeutics.

Luis A. Diaz, M.D.

Luis is a leading authority in oncology, having pioneered several genomic diagnostic and therapeutic approaches for cancer. He is an attending physician at the Johns Hopkins Hospital and is currently a member of the Ludwig Center and Director of the Swim Across America Lab.

 

Officers
Howard B. Kaufman, MBA.

Howie is Chief Executive Officer at PapGene and has over 25 years of management experience in small and large companies operating in FDA-regulated environments. Most recently he served as Senior Director, Technology Assessment and Business Development at Hologic where he led the assessment of new diagnostic markets and emerging technologies.

Isaac Kinde, M.D., Ph.D.

Isaac is Chief Scientific Officer at PapGene and is a nationally recognized expert in molecular cancer diagnostics. His inventions include two core PapGene patents being licensed from Johns Hopkins University. Isaac has contributed to other key advancements in the field of genetic cytology.

 

Technology

At PapGene, Inc. we are developing innovative tests that uncover early-stage cancers from the analysis of easily accessible body fluids. Our approach is to detect cancers by the same genetic defects (acquired mutations) that drive cancer growth.

The key challenge in identifying cancers through their mutations is the high level of accuracy required by such tests. In the body fluids of patients with early-stage cancers, mutations indicative of cancers are rare in comparison to the large excess of DNA contributed by healthy cells.

PapGene, Inc.’s proprietary next-generation DNA sequencing technology overcomes this accuracy barrier. Powered by error-reducing Safe-SeqS technology licensed from Johns Hopkins University, our proprietary technology can reliably distinguish the rare, genuine mutations indicative of cancers from technical artifacts.

News

  • Connector.Connector.

    PapGene, Inc. Awarded NIH Contract for the Surveillance of Recurrent Bladder Cancer

    PR Newswire (2016)
    Read Article

  • Connector.Connector.

    PapGene, Inc. Awarded Grant for Test to Detect Ovarian and Endometrial Cancers

    PR Newswire (2016)
    Read Article

  • Connector.Connector.

    Startup PapGene Develops DNA Test for Ovarian, Endometrial Cancers

    Johns Hopkins Technology Ventures (2015)
    Read Article

  • Connector.Connector.

    The Maryland Daily Record Names PapGene, Inc. as a 2015 Innovator of the Year

    The Daily Record (2015)

    Read Article

  • Connector.Connector.

    Johns Hopkins Startup Could Help Detect Ovarian Cancer

    Baltimore Business Journal (2015)
    Read Article

  • Connector.Connector.

    Pap Test Could Help Find Cancers of Uterus and Ovaries

    The New York Times (2013)
    Read Article


PUBLICATIONS


  • Connector.Connector.

    Evaluation of DNA From the Papanicolaou Test to Detect Ovarian and Endometrial Cancers

    Science Translational Medicine (2013)
    Go To Publication

  • Connector.Connector.

    Detection and Quantification of Rare Mutations With Massively Parallel Sequencing

    PNAS (2011)
    Go To Publication

Careers

  • Connector.Connector.

    Inquiries

    PapGene is always interested in hearing from qualified personnel interested in joining our team, particularly from those with experience in massively parallel sequencing, bioinformatics, or high-complexity CLIA testing.

    Interested candidates should e-mail a cover letter and their resume to hr@PapGeneInc.com.

 
For more information,
contact us
 
 

PapGene, Inc.

810 Wyman Park Drive
Baltimore, MD 21211

info@PapGeneInc.com
410-575-1264

FCOI


Your Name (required)

Your Email (required)

Subject

Your Message